Sharps Technology Surges 157% After New Agreements with Nephron SC and Sterile Compounding Centers; Options Trader Nic Chahine Achieves Impressive Win Rate of 83%

Sharps Technology Inc. (NASDAQ:STSS) shares experienced a significant increase in value on Tuesday, up 157%, after the company announced new agreements with Nephron SC and Nephron Sterile Compounding Centers. The stock had previously decreased by 42% over the past year, but the new agreements have reversed that trend. Under the five-year Purchase Agreement with Nephron SC and Nephron Sterile, Nephron has committed to exclusively use Sharps Technology as its pre-filled copolymer syringe manufacturer, and the companies have agreed to purchase a minimum aggregate of approximately $188.5 million worth of syringes from Sharps Technology. Additionally, in March, STSS signed a cooperative selling and distribution pact with Italy’s Roncadelle Operations to sell and distribute each other’s products in their respective areas of influence.

Meanwhile, options trader Nic Chahine has been able to achieve an average profit of 27% every 20 days through his options buys without selling covered calls or spreads. This is an impressive feat given that most traders struggle to achieve even a winning percentage of 27%. Chahine’s success can be attributed to his unique strategy when it comes to trading options. He has an impressive 83% win rate, which sets him apart from other traders in the market. By leveraging his expertise and experience, Chahine has been able to consistently generate profits through his options trades, making him one of the top performers in this competitive field.